| 0.9246 0.053 (6.08%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.24  |
1-year : | 1.4 |
| Resists | First : | 1.06 |
Second : | 1.2 |
| Pivot price | 1.04 |
|||
| Supports | First : | 0.85 | Second : | 0.7 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 1.05 |
| MA(100) : | 1.31 |
MA(250) : | 1.56 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 7.8 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 2.54 | Low : | 0.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DNA ] has closed above bottom band by 16.0%. Bollinger Bands are 10.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.96 | 0.96 - 0.97 |
| Low: | 0.84 - 0.85 | 0.85 - 0.85 |
| Close: | 0.91 - 0.92 | 0.92 - 0.94 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Thu, 18 Apr 2024
Ginkgo Bioworks (NYSE:DNA) Shares Up 5% - MarketBeat
Wed, 17 Apr 2024
Ginkgo Bioworks (NYSE:DNA) Reaches New 1-Year Low at $0.85 - MarketBeat
Tue, 16 Apr 2024
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery ... - Quantisnow
Sun, 14 Apr 2024
Recent uptick might appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners after losing 61% over ... - Yahoo Lifestyle UK
Thu, 11 Apr 2024
What's Going On With Ginkgo Bioworks Stock? - Ginkgo Bioworks Holdings (NYSE:DNA) - Benzinga
Thu, 28 Mar 2024
Ginkgo stock gains after DARPA ICE contract (NYSE:DNA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1,650 (M) |
| Shares Float | 1,120 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 83.8 (%) |
| Shares Short | 270,830 (K) |
| Shares Short P.Month | 255,720 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | 0 % |
| Operating Margin | -515.6 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -63.1 % |
| Qtrly Rev. Growth | -64.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -296 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -2.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 1.68 |
| Price to Sales | 6.06 |
| Price to Cash Flow | -5.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|